Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Bioprocessing

What if the biggest advancement in bioprocessing isn’t a new AI algorithm or cutting-edge bioreactor, but a renewed focus on the foundational skills that drive innovation—and a clear-eyed look at what AI can (and can’t) really do for the industry right now?

Bioprocessing

How do you bridge the gap between cutting-edge industrial bioprocessing and the academic world tasked with training the next generation?

Innovation

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

Innovation

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Bioprocessing

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tools

Bioprocessing

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tool

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Bioreactor scale-up failures are still one of the top reasons promising cell therapies never reach the clinic. Traditional “power per volume” scale-up is often just a best guess—putting product quality and timelines at risk.

Bioprocessing

Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?

Data & Analytics

What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?

Data & Analytics

Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.

Data & Analytics

Leveraging digital models and AI-powered tools can make all the difference for both R&D and manufacturing, but finding the right starting point—and justifying the investment—can feel overwhelming.

Data & Analytics

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Data & Analytics

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Biotech Success

You may have the next blockbuster molecule in your pipeline.

Biotech Success

Many bioproduction development projects fail due to inadequate stakeholder engagement.

Biotech Success

Lars Brandén has travelled an uncommon route from a youthful fascination with viruses to leading biology at Kolibri, a Paris-based company developing acoustic bioreactors and novel transfection chemistries.

Biotech Success

I want to let you in on a secret. Truly transformative bioprocess development is not just about creative brainstorming in the lab.

Biotech Success

Biomanufacturing has evolved from producing simple recombinant hormones to assembling highly complex biologics in living systems.

Biotech Success

Bringing a new therapeutic biologic from discovery to clinic is a delicate balancing act of cutting‑edge science, tight regulatory timelines, and rapid iteration. One misalignment—whether in documentation, communication, or data interpretation—can quickly derail months of hard work.

Innovation

Bioreactors have relied on impellers for decades, yet these mechanical mixers create shear forces that damage fragile cells such as induced pluripotent stem cells, natural killer cells, and dinoflagellates.

Innovation

Biopharmaceutical production has undergone remarkable transformations in recent decades, driven by the growing complexity of therapeutic molecules and the demand for faster, more efficient, and more flexible manufacturing strategies.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.